159 related articles for article (PubMed ID: 34906512)
1. Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity.
Fortuno C; McGoldrick K; Pesaran T; Dolinsky J; Hoang L; Weitzel JN; Beshay V; San Leong H; James PA; Spurdle AB
Genet Med; 2022 Mar; 24(3):673-680. PubMed ID: 34906512
[TBL] [Abstract][Full Text] [Related]
2. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
[TBL] [Abstract][Full Text] [Related]
3. Somatic TP53 variants frequently confound germ-line testing results.
Weitzel JN; Chao EC; Nehoray B; Van Tongeren LR; LaDuca H; Blazer KR; Slavin T; Facmg DABMD; Pesaran T; Rybak C; Solomon I; Niell-Swiller M; Dolinsky JS; Castillo D; Elliott A; Gau CL; Speare V; Jasperson K
Genet Med; 2018 Aug; 20(8):809-816. PubMed ID: 29189820
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of
Schwartz AN; Hyman SR; Stokes SM; Castillo D; Tung NM; Weitzel JN; Rana HQ; Garber JE
JCO Precis Oncol; 2021 Nov; 5():1677-1686. PubMed ID: 34994652
[TBL] [Abstract][Full Text] [Related]
5. Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
Castillo D; Yuan TA; Nehoray B; Cervantes A; Tsang KK; Yang K; Sand SR; Mokhnatkin J; Herzog J; Slavin TP; Hyman S; Schwartz A; Ebert BL; Amos CI; Garber JE; Weitzel JN
Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1621-1629. PubMed ID: 35654360
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
7. TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis.
Kawai M; Iijima-Yamashita Y; Taguchi I; Kataoka M; Sanada M; Murakami Y; Kitagawa C; Hattori H
Am J Case Rep; 2022 Jun; 23():e936455. PubMed ID: 35700150
[TBL] [Abstract][Full Text] [Related]
8. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
Fortuno C; Lee K; Olivier M; Pesaran T; Mai PL; de Andrade KC; Attardi LD; Crowley S; Evans DG; Feng BJ; Foreman AKM; Frone MN; Huether R; James PA; McGoldrick K; Mester J; Seifert BA; Slavin TP; Witkowski L; Zhang L; Plon SE; Spurdle AB; Savage SA;
Hum Mutat; 2021 Mar; 42(3):223-236. PubMed ID: 33300245
[TBL] [Abstract][Full Text] [Related]
9. Clinical management of TP53 mosaic variants found on germline genetic testing.
Ward A; Farengo-Clark D; McKenna DB; Safonov A; Good M; Le A; Kessler L; Shah PD; Bradbury AR; Domchek SM; Nathanson KL; Powers J; Maxwell KN
Cancer Genet; 2024 Jun; 284-285():43-47. PubMed ID: 38677009
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
Weber-Lassalle K; Harter P; Hauke J; Ernst C; Kommoss S; Marmé F; Weber-Lassalle N; Prieske K; Dietrich D; Borde J; Pohl-Rescigno E; Reuss A; Ataseven B; Engel C; Stingl JC; Schmutzler RK; Hahnen E
Hum Mutat; 2018 Dec; 39(12):2040-2046. PubMed ID: 30216591
[TBL] [Abstract][Full Text] [Related]
11.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
12. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
13. Evolution of germline TP53 variant classification in children with cancer.
Tallis E; Scollon S; Ritter DI; Plon SE
Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
[TBL] [Abstract][Full Text] [Related]
14. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
Fortuno C; Mester J; Pesaran T; Weitzel JN; Dolinsky J; Yussuf A; McGoldrick K; Garber JE; Savage SA; Khincha PP; Gareth Evans D; Achatz MI; Nichols KE; Maxwell KN; Schiffman JD; Sandoval R; ; James PA; Spurdle AB
Hum Mutat; 2020 Sep; 41(9):1555-1562. PubMed ID: 32485079
[TBL] [Abstract][Full Text] [Related]
15. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
[TBL] [Abstract][Full Text] [Related]
16. An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy.
Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Tavtigian SV; Goldgar D; Spurdle AB; James PA
Hum Mutat; 2021 Oct; 42(10):1351-1361. PubMed ID: 34273903
[TBL] [Abstract][Full Text] [Related]
17. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
[TBL] [Abstract][Full Text] [Related]
19. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
20. TP53 variants of uncertain significance: increasing challenges in variant interpretation and genetic counseling.
Bittar CM; Vieira IA; Sabato CS; Andreis TF; Alemar B; Artigalás O; Galvão HCR; Macedo GS; Palmero EI; Ashton-Prolla P
Fam Cancer; 2019 Oct; 18(4):451-456. PubMed ID: 31321604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
